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A B S T R A C T
Polymyxins (polymyxin B and colistin) are older bactericidal antibiotics that are increasingly used to
treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria. However, dosing and
clinical use of these drugs vary widely. This survey was undertaken to reveal how polymyxins are used
worldwide. Data were collected through a structured online questionnaire consisting of 24 questions
regarding colistin usage patterns and indications as well as colistin dosage for adult patients. The
questionnaire was disseminated in 2011 to relevant experts worldwide and was completed by 284
respondents from 56 different countries. Respondents from 11/56 countries (20%) had no access to
colistin; 58/284 respondents (20.4%) reported that in 2010 they experienced that colistin was not
available when needed. Formulations of polymyxins used were reported as: colistimethate sodium
(48.6%); colistin sulfate (14.1%); both (1.4%); polymyxin B (1.4%); and unknown. Intravenous
formulations were used by 84.2%, aerosolised or nebulised colistin by 44.4% and oral colistin for
selective gut decontamination by 12.7%. Common indications for intravenous colistin were ventilator-
associated pneumonia, sepsis and catheter-related infections with MDR Gram-negative bacteria. Only
21.2% of respondents used a colistin-loading dose, mainly in Europe and North America. This survey
reveals that the majority of respondents use colistin and a few use polymyxin B. The survey results show
that colistin is commonly underdosed. Clear guidance is needed on indications, dosing and antibiotic
combinations to improve clinical outcomes and delay the emergence of resistance. Colistin should be
considered a last-resort drug and its use should be controlled. International guidelines are urgently
needed.
 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. 
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Severe multidrug-resistant (MDR) Gram-negative infections
are increasing worldwide [1]. The emergence of carbapenem
resistance in Gram-negative bacteria is of extreme concern as few
therapeutic options remain [1]. For this reason, clinicians are* Corresponding author at: Wellcome Trust Major Overseas Program, Oxford
University Clinical Research Unit, National Hospital for Tropical Diseases, Hanoi,
Viet Nam.
E-mail address: Heiman.wertheim@gmail.com (H. Wertheim).
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http://dx.doi.org/10.1016/j.jgar.2013.03.012increasingly using an older class of antibiotics, namely the
polymyxins, most commonly colistin (polymyxin E) [2].
Colistin is a bactericidal antibiotic with a broad Gram-negative
spectrum, consisting of a mixture of colistin A and colistin B,
differing in their fatty acid side chain. The active compound was
isolated from the bacterium Bacillus polymyxa var. colistinus in
1949 and was used in patients for the ﬁrst time in 1959.
Polymyxins have been used rarely since the 1970s when less
toxic aminoglycosides and other antibiotics came on the market
[3]. Polymyxins, developed over 50 years ago, have not been
subjected to the rigorous studies to optimise dosing regimens and
to demonstrate efﬁcacy that are currently required by regulatory
agencies for new drugs [3]. The appropriate dosing schedule for
these drugs, how long they should be administered, and with
which other antibiotics they should be used are questions
remaining to be answered [2–5]. Insights into pharmacodynamicblished by Elsevier Ltd. Open access under CC BY-NC-SA license.
Table 1
Characteristics of the respondents regarding country, hospital and profession
(N = 284).
Characteristic n (%)
World regions
Europe 115 (40.5)
South America 64 (22.5)
North America 33 (11.6)
Oceania 35 (12.3)
Asia 26 (9.2)
Africa 11 (3.9)
Hospital typea
Primary care 47 (16.5)
Secondary care 74 (26.1)
Tertiary care 205 (72.2)
Teaching 185 (65.1)
Profession
Infectious diseases doctor 144 (50.7)
Clinical microbiologist 35 (12.3)
Intensive care doctor 50 (17.6)
Pharmacist 22 (7.7)
Other 33 (11.6)
a Respondents were able to select more than one possibility, therefore ﬁgures do
not add to 100% (e.g. tertiary hospital and teaching are not mutually exclusive;
some respondents worked at several places).
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partly elucidated, but many questions still remain [6]. The lack of
documented experience with the drug and the availability of
various forms of polymyxins with different concentrations and
even units used in different dosing schemes have also led to
inappropriate use. Furthermore, access to polymyxin drugs and
other ‘forgotten antibiotics’ is limited – even in developed nations
– for economic reasons [7].
Considering that no new antibiotics covering MDR Gram-
negative bacteria can be expected to reach the market in the near
future, it is essential to use the polymyxin class of antibiotics
optimally and rationally [8,9]. Providing early adequate therapy is
critical in patients with severe infections caused by MDR bacteria
[8,9]. Underdosing runs the risk of treatment failure, poor outcome
and potentially the development and spread of polymyxin
resistance [6]. It is currently unknown which doses clinicians
use and whether they are using colistin loading doses. It is also not
known with which other drugs colistin is being combined.
To assess global polymyxin availability and parenteral use
practices, an online survey was conducted.
2. Methods
To assess global systemic polymyxin use, a 24-question survey
(see Appendix) was developed that sought information on:
characteristics of the respondents; indications for use of polymyxins;
access to polymyxins and drug type; cost of polymyxins; dosing of
polymyxins; adverse events; antibiotic combinations; and research
needs. Topical polymyxin use was not covered in this survey.
Supplementary material related to this article found, in the
online version, at doi:10.1016/j.jgar.2013.03.012.
The questionnaire was peer-reviewed by three working groups
working on antibiotic resistance: (i) Global Antibiotic Resistance
Partnership (GARP); (ii) Action on Antibiotic Resistance (ReAct);
and (iii) the Antimicrobial Stewardship Working Group of the
International Society of Chemotherapy. The ﬁnal version was
piloted and then made freely available through an online survey
website (http://www.freeonlinesurveys.com).
Professionals (e.g. infectious diseases doctors, pharmacists,
microbiologists, intensive care physicians) in relevant networks
were invited by email to complete the questionnaire. All invitees
were asked to forward the email to anyone they considered
relevant to complete the survey. The survey was open from 1 June
to 1 November 2011. Data were analysed using descriptive
statistics using SPSS v.15 (SPSS Inc., Chicago, IL).
3. Results
3.1. Respondent characteristics
The survey was completed by 284 respondents from 56 different
countries (Table 1 and Fig. 1). The majority of respondents were from
Europe, followed by the Americas, and most worked in tertiary care
teaching hospitals. Approximately one-half of the respondents
worked in hospitals with more than 500 beds. Most of the hospitals
had an intensive care unit (89.4%), department of surgery (92.6%)
and a microbiology laboratory (91.9%). All respondents had a
medical background relevant to the survey (Table 1).
3.2. Polymyxin drug access
Respondents in 11 (20%) of 56 countries reported that they had
no access to colistin at the time of the survey. Lack of access was
reported from all continents except Oceania and North America.
The countries for which no access was reported, included Bolivia,
Guatemala, Indonesia, Laos, Norway, Portugal, Russia, Uzbekistan,Venezuela, Vietnam and Yemen (Fig. 1; data by respondent
available from the corresponding author by request). The survey
also asked about the consistency of supply of polymyxin drugs in
the respondents’ institutions. Of the 284 respondents, 58 (20.4%)
reported that these drugs were unavailable for patients at least
once during the preceding year (Fig. 1).
Various forms of polymyxin drugs are available and used
worldwide. The majority of respondents used colistimethate sodium
(48.6%), followed by colistin sulfate (14.1%), both forms of colistin
(1.4%) and polymyxin B (1.4%), and the remainder did not know the
exact formulation. Eighty percent of the reported colistin sulfate use
originated from Europe and South America. No colistin sulfate was
reported from Asia. Polymyxin B was used only in South America
(Brazil and Panama) and Asia (Singapore). As Polymyxin B is rarely
used, further analysis here is limited to colistin.
The number of patients [median; interquartile range (IQR)]
treated with polymyxin drugs by region in the year 2010 was: 30
(IQR 100) in Africa; 32 (IQR 300) in Asia; 5 (IQR 24) in Europe; 2
(IQR 20) in North America; 2 (IQR 4) in Oceania; and 15 (IQR 30) in
South America.
3.3. Indications for colistin
Colistin is administered via different routes, depending on the
indication. Of the 284 respondents, 84.2% used colistin intrave-
nously, 44.4% used aerosolised or nebulised colistin and 12.7% used
oral colistin for selective gut decontamination. Common indica-
tions for intravenous colistin use were ventilator-associated
pneumonia, sepsis and catheter-related infections with MDR
Gram-negative bacteria. Nebulised colistin was often used in cystic
ﬁbrosis patients. Colistin was used most commonly against
Acinetobacter baumannii and Pseudomonas aeruginosa. Oral colistin
for selective gut decontamination was most frequently reported
from Europe, followed by North America. No African respondents
reported oral colistin use.
3.4. Dosing of colistin
The dosing schedule for an adult patient with a weight of 70 kg
and normal renal function (the standard case posed in the
questionnaire) varied considerably, partly reﬂecting the different
types of formulations. Dosing data were reported in million
Fig. 1. World map showing the locations of the respondents. The map includes information on the availability of colistin and whether the respondent uses a colistin-loading
dose (more detailed information by respondent available from the corresponding author by request).
Table 3
Response to what drugs are used for combination therapy with colistin.
Frequency (%)
Never Uncommon Common
Carbapenem 24.5 31.7 43.8
Gentamicin 41.3 38.8 20.0
Tigecycline 47.4 34.2 18.4
Rifampicin 51.9 29.8 18.3
Piperacillin/tazobactam 49.3 35.5 15.2
Fluoroquinolone 52.8 39.6 7.7
Fosfomycin 81.5 12.0 6.5
Minocycline 81.1 14.5 4.4
Othera 64.3 23.1 12.6
a Other includes cephalosporins, trimethoprim/sulfamethoxazole, glycopeptide,
linezolid and doxycycline.
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(see Table 2 for dosing conversion). For those reporting in MIU, the
median total daily dose was 6.0 MIU (range 1.5–9.0 MIU) adminis-
tered three times per day (range 1–4 times per day). For those
reporting in mg/kg/day, the median colistin dose was 5 mg/kg/day
(range 1.5–6.0 mg/kg/day). Those who also administered a loading
dose (see below) reported a higher maintenance dose compared
with those who did not use a loading dose: median of 9 MIU versus 6
MIU. Approximately one-quarter (26.4%) of the respondents were
dosing their patients in the lower range (2.5 mg/kg/day or
6 MIU). The median duration of colistin treatment was 14 days.
Less than one-third (29%) reported adjusting the dose in obese
patients. Dosing strategies for patients on haemodialysis varied,
most indicating that they halved the dose.
Evidence from pharmacokinetic/pharmacodynamic (PK/PD) stud-
ies indicates that a colistin loading dose may be beneﬁcial for patients
with severe MDR Gram-negative infections. Of the respondents, only
21.2% reported a loading dose and most of these were in Europe and
North America. No Asian respondent reported that they used a
loading dose. In Europe, the most common loading dose was 9 MIU
and in South America it was 4.5 MIU (the loading dosage was
provided via a separate email request to those using a loading use).
3.5. Drug combinations
Table 3 lists the antibiotics used with colistin, according to the
relative frequency. The most common antibiotic combination wasTable 2
Conversion table milligrams to international units (IU) for someone weighing 70 kg.
1 mg colistin base activity ﬃ33,250 IU
5 mg/kg colistin base activity = 350 mg/day ﬃ11.5 MIU/day
1 mg colistimethate sodium ﬃ12,500 IU
9 MIU ﬃ720 mg colistimethate sodium ﬃ3.9 mg/kg colistin base activity
Source: AIDA project.
MIU, million international units.with a carbapenem. Other relatively common combinations were
aminoglycosides, tigecycline, rifampicin and piperacillin/tazobac-
tam. According to respondents, the choice of a second antibiotic
depends on the type of infection being treated and the
susceptibility proﬁle of the cultured bacteria, if available. The
most important drugs to combine with polymyxins to study in a
clinical trial are considered to be tigecycline and piperacillin/
tazobactam, according to a majority of survey respondents.
4. Discussion
To our knowledge, this is the ﬁrst global survey on polymyxin
use. Respondents were a self-selected group and we do not portray
the results as an unbiased sample. Despite this, the study provides
important insights into the current global pattern of access to and
use of these drugs. As only a few respondents reported polymyxin
B use, the discussion focuses on colistin.
In general, the indications for use of systemic colistin are similar
across the regions: severe infections caused by MDR Gram-negative
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major variations in the dosing regimens, with several sites using
relatively low doses, and a loading dose of colistin was not reported
by most respondents. PK/PD studies found that it takes several days
to develop adequate concentrations of colistin in human plasma
[5,10]. These studies suggest that loading doses are required to
achieve adequate levels of colistin as early as possible [5,10].
Providing early adequate therapy is critical in patients with severe
infections due to MDR bacteria [10].
In a recent discussion on dosing of colistin, and taking into
account the PK/PD properties of colistin, a 9 MIU loading dose and
4.5 M IU every 12 h was suggested to be one of the optimum dosing
alternatives (colistin fact sheet available at http://aida-project.eu).
In particular, the loading dose was regarded to be essential, since
the simulations strongly indicate that it takes up to several days
before steady state is reached [10]. However, even then
concentrations required for optimal efﬁcacy may not be reached.
In addition, PK proﬁles vary widely between patients, suggesting
that therapeutic drug monitoring could be beneﬁcial.
Clinicians reported reluctance to use higher doses because of
concerns about toxicity [3]. However, based on various studies,
these concerns may be misplaced and respondents that use a
loading dose conﬁrm little toxicity issues of this strategy. Colistin
has been shown to have a better safety proﬁle than thought
previously, perhaps even better than the safety proﬁle of
aminoglycosides [3,11,12]. The risk of toxicity may be favoured
above inadequate treatment of a severe infection due to MDR
bacteria. Clearly, more should be known about these drugs, but we
are concerned that underdosing may be a serious issue as this is
related to the emergence of resistant bacteria [13].
However, excessive use of colistin needs to be addressed. More
than 10% of the respondents mentioned that they also used
polymyxins as part of a selective gut decontamination regimen.
The use of polymyxins for this purpose needs to be weighted by the
risk of resistance development in a world where carbapenem
resistance is emerging and spreading [1]. Furthermore, colistin is
used in large amounts in agriculture, particularly in Asia (Do Thuy
Nga, GARP co-ordinator Vietnam, personal communication). The
reasons for use in agriculture require further investigation and a
case made for banning polymyxins for agricultural use.
This survey revealed important variations in the use of
polymyxins across the world, supporting the need for the
development of clear guidelines covering the indication, dosage
and duration of polymyxins. Many questions regarding dosing and
combinations with other antibiotics remain, and studies are under
way to answer at least some of these. However, guidelines can and
should be developed based on current evidence and revised as new
information becomes available. The European Union-funded AIDA
project tries to address these issues and has made colistin fact
sheets and dosing conversion tables available (http://aida-projec-
t.eu/back-ground-information/fact-sheets/91-fact-sheets-public/
84-colistin-fact-sheet-public). As new classes of antibiotics for
MDR Gram-negative bacteria are not within sight, we need to
preserve these last-resort antibiotics.
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